Patient-reported outcomes of the prognostic nutritional index for resectable esophageal squamous cell carcinoma
- PMID: 40809259
- PMCID: PMC12340319
- DOI: 10.21037/jtd-2025-1229
Patient-reported outcomes of the prognostic nutritional index for resectable esophageal squamous cell carcinoma
Abstract
Background: The prognostic nutritional index (PNI) involves both the nutritional status and immune function as crucial factors linked to the prognosis of various gastrointestinal cancers. The relationship between the PNI and postoperative quality of life (QOL) in patients with esophageal cancer (EC) has not been examined. This study sought to examine the effects of the PNI on the postoperative patient-reported outcomes (PROs) of patients with esophageal squamous cell carcinoma (ESCC).
Methods: Consecutive ESCC patients undergoing minimally invasive McKeown esophagectomy at a single center from April 2019 to December 2020 were enrolled in this study. The patients were allocated to the PNI-high group (PNI ≥45) and PNI-low group (PNI <45). The longitudinal PROs were handled to compare the functions and symptoms using a linear mixed-effect models. The M.D. Anderson Symptom Inventory (MDASI) and the European Organization for Research and Treatment of Cancer (EORTC) questionnaires were used to assess patients' symptoms and QOL.
Results: A total of 274 patients were included in the study. Patients with esophageal cancer experienced a decline in functional status and significant esophageal cancer-related symptoms shortly after surgery. When PNI was less than 45, a higher PNI might be associated with improved functional status and more obvious symptoms such as pain, problems with taste, sadness, shortness of breath, and drowsiness (P<0.05).
Conclusions: There might be a non-linear association between PNI and the postoperative health-related QOL of ESCC patients. It was emphasized that individualized nutritional intervention should be provided for patients with PNI lower than 45.
Keywords: Prognostic nutritional index (PNI); esophageal squamous cell carcinoma (ESCC); esophagectomy; patient-reported outcomes (PROs).
Copyright © 2025 AME Publishing Company. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-1229/coif). The authors have no conflicts of interest to declare.
Figures


Similar articles
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
The investigation of factors influencing the prognostic nutritional index in patients with esophageal cancer-a cross-sectional study.J Thorac Dis. 2025 Jul 31;17(7):5065-5077. doi: 10.21037/jtd-2025-120. Epub 2025 Jul 17. J Thorac Dis. 2025. PMID: 40809260 Free PMC article.
-
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280. Health Technol Assess. 2008. PMID: 18547499